Chapter 3 Market and Technology Background
- Neurological Disorders: Overview
- Disease Background
- Parkinson Disease
- Alzheimer Disease
- Schizophrenia
- Bipolar Disorders
- Depression
- Epileptic Disorders
- Autism Spectrum Disorders
- Neuroprotective Agents
- Neuroprotective Strategies
- Drug Development Regulations
- U.S.
- Canada
- Mexico
- Europe
- Asia-Pacific
- ROW
- Reimbursement Landscape
Chapter 4 Market Dynamics
- Market Drivers
- Government and NGO Initiatives in Creating Awareness
- Growing Geriatric Population with Neurological Disorders
- Increasing Global Incidence of Neurological Disorders
- Research Initiatives in Neurology
- Accelerated Approvals for Drugs Used in Rare Diseases
- Market Restraints
- Patent Expirations of Branded Drugs and Emergence of Generics
- Adverse Side Effects
- High Cost of Drug Development
Chapter 5 Global Market for Neurology
- Global Market for Neurology, by Disease Indication
Chapter 6 Global Market for Parkinson Disease
- Anti-Parkinson’s Drugs: Market Overview
- Anti-Parkinson’s Drugs Market, by Drug Class
- Dopaminergic
- Market Size and Forecast
- Market Analysis
- Dopamine Agonists
- Market Size and Forecast
- Market Analysis
- Enzyme Inhibitors Market
- Market Size and Forecast
- Market Analysis
- Other Anti-Parkinson’s Drugs
- Market Size and Forecast
- Market Analysis
- Anti-Parkinson’s Drugs Market, by Region
- North America
- Market Size and Forecast
- Market Analysis
- Europe
- Market Size and Forecast
- Market Analysis
- Asia-Pacific
- Market Size and Forecast
- Market Analysis
- South America
- Market Size and Forecast
- Market Analysis
- Middle East and Africa
- Market Size and Forecast
- Market Analysis
- Global Company Share Analysis
Chapter 7 Global Market for Alzheimer Disease
- Market Overview
- Global Alzheimer Drugs Market, by Mechanism of Action
- AChEIs
- Market Size and Forecast
- Market Analysis
- NMDA Drugs
- Market Size and Forecast
- Market Analysis
- Global Alzheimer Drugs Market, by Region
- North America
- Market Size and Forecast
- Market Analysis
- Europe
- Market Size and Forecast
- Market Analysis
- Rest of the World
- Market Size and Forecast
- Market Analysis
- Industry Structure
- Impact of Generic AD Therapeutics
Chapter 8 Global Market for Psychotic Disorders
- Market Overview
- Global Antipsychotic Drugs Market, by Drug Class
- D2 Antagonists
- Market Size and Forecast
- Market Analysis
- D2/5HT2A Antagonists
- Market Size and Forecast
- Market Analysis
- D2 Partial Agonists
- Market Size and Forecast
- Market Analysis
- Global Antipsychotic Drugs Market, by Region
- North America
- Market Size and Forecast
- Market Analysis
- Europe
- Market Size and Forecast
- Market Analysis
- Asia-Pacific
- Market Size and Forecast
- Market Analysis
- South America
- Market Size and Forecast
- Market Analysis
- Middle East and Africa
- Market Size and Forecast
- Market Analysis
- Global Company Share Analysis
- Impact of Generic Antipsychotic Drugs on the Market
Chapter 9 Global Market for Epileptic Disorders
- Market Overview
- Market Trends
- Global Anti-Epileptic Drugs Market, by Drug Class
- First Generation Anti-Epileptic Drugs
- Market Size and Forecast
- Market Analysis
- Second Generation Anti-Epileptic Drugs
- Market Size and Forecast
- Market Analysis
- Third Generation Anti-Epileptic Drugs
- Market Size and Forecast
- Market Analysis
- Global Anti-Epileptic Drugs Market, by Region
- North America
- Market Size and Forecast
- Market Analysis
- Europe
- Market Size and Forecast
- Market Analysis
- Asia-Pacific
- Market Size and Forecast
- Market Analysis
- South America
- Market Size and Forecast
- Market Analysis
- Middle East and Africa
- Market Size and Forecast
- Market Analysis
- Anti-Epileptic Drugs Market Competitive Landscape
Chapter 10 Global Market for Autism Spectrum Disorders
- Market Overview
- Antipsychotics
- Antidepressants
- Stimulants
- Anticonvulsants
- Global ASD Therapeutics Market, by Label Information
- Labeled ASD Pharmaceuticals
- Market Size and Forecast
- Market Analysis
- Off-label Pharmaceuticals
- Market Size and Forecast
- Market Analysis
- Global ASD Therapeutics Market, by Region
- North America
- Market Size and Forecast
- Market Analysis
- Europe
- Market Size and Forecast
- Market Analysis
- Rest of the World
- Market Size and Forecast
- Market Analysis
- Global ASD Therapeutics Market Industry Structure
Chapter 11 Global Market for Brain Tumor Therapeutics
- Market Overview
- Brain Tumor Therapeutics Market, by Therapy Type
- Chemotherapy
- Market Size and Forecast
- Market Analysis
- Targeted Therapy
- Market Size and Forecast
- Market Analysis
- Immunotherapy
- Immunotherapeutic Agents
- New Developments
- Brain Tumor Therapeutics Market, by Region
- North America
- Market Size and Forecast
- Market Analysis
- Europe
- Market Size and Forecast
- Market Analysis
- Asia-Pacific
- Market Size and Forecast
- Market Analysis
- Rest of the World
- Market Size and Forecast
- Market Analysis
- Company Share Analysis
Chapter 12 Pipeline Analysis
- Overview of the Drug Development Process
Chapter 13 Competitive Landscape
- Key Strategies Adopted by Market Players
- Mergers and Acquisitions
- Agreements and New Product Launches
Chapter 14 Company Profiles
- Abbvie
- Acadia Pharmaceuticals, Inc.
- Alembic Pharmaceuticals Ltd.
- Alexza Pharmaceuticals
- Alkermes Plc
- Allergan Plc
- Apotex, Inc.
- Astrazeneca Plc
- Aurobindo Pharma
- Autism Therapeutics
- Avanir Pharmaceuticals Inc.
- Boehringer Ingelheim
- Bristol-Myers Squibb Co.
- Biogen
- Daiichi Sankyo Co., Ltd.
- Dr. Reddy’S Laboratories Ltd.
- Eli Lilly And Co.
- Eisai Co. Ltd.
- F. Hoffmann-La Roche Ag
- Glaxosmithkline Plc
- Gedeon Richter Plc
- Immunocellular Therapeutics, Ltd.
- Johnson & Johnson
- Lannett Co., Inc.
- H. Lundbeck A/S
- Lupin Ltd.
- Mallinckrodt
- Merck & Co
- Mylan Nv
- Nextsource Biotechnology Llc
- Novartis Ag
- Otsuka Holdings Co., Ltd.
- Pfizer Inc.
- Sanofi
- Sumitomo Dainippon Pharma Co., Ltd.
- Sun Pharmaceutical Industries Ltd. (Sun Pharma)
- Teva Pharmaceutical Industries Ltd.
- Torrent Pharmaceuticals Ltd.
- United Therapeutics Corp.
- UCB SA
List of Tables
Summary Table: Global Market for Neurology, by Disease Indication, Through 2024
Table 1: Current Orphan Drugs Designations for Brain Tumors
Table 2: Global Market for Neurology, by Disease Indication, Through 2024
Table 3: Global Neurology Market for Anti-Parkinson's Drugs, by Drug Class, Through 2024
Table 4: Global Neurology Market for Anti-Parkinson's Drugs, by Region, Through 2024
Table 5: Global Neurology Market for Alzheimer Drugs, by Mechanism of Action, Through 2024
Table 6: Global Neurology Market for Alzheimer Drugs, by Region, Through 2024
Table 7: Global Ranking of Leading Players in Alzheimer’s Disease Drugs, by Company
Table 8: Global Neurology Market for Antipsychotic Drugs, by Mechanism of Action, Through 2024
Table 9: D2 Antagonist Drugs: Market Presence
Table 10: Adverse Effects Profile of D2 Antagonist/Typical Antipsychotic Drugs
Table 11: Global Neurology Market for Antipsychotic Drugs, by Region, Through 2024
Table 12: Prevalence of Serious Mental Illness Among Adults in the U.S., by State, 2017
Table 13: Prevalence of Mental Illness in U.S., by Disease Indication, 2017
Table 14: Global Neurology Market for Anti-Epileptic Drugs, by Segment, Through 2024
Table 15: Global Neurology Market for Anti-Epileptic Drugs, by Region, Through 2024
Table 16: Global Neurology Market for ASD Therapeutics, by Label Information, Through 2024
Table 17: Selected Late-Stage Autism Treatments
Table 18: Global Neurology Market for ASD Therapeutics, by Region, Through 2024
Table 19: Global Market Ranking of Leading Players in ASD Drugs, by Company
Table 20: Global Neurology Market for Brain Tumor Therapeutics, by Therapy Type, Through 2024
Table 21: FDA-Approved Drugs Used in Brain Tumor Chemotherapy
Table 22: Dosage and Administration of Temozolomide for Brain Tumors
Table 23: Current Brain Tumor Clinical Trials: Temozolomide
Table 24: Current Brain Tumor Clinical Trials Involving Lomustine
Table 25: Current Brain Tumor Clinical Trials involving Carmustine
Table 26: PCV Regimen: Brain Tumor Chemotherapy
Table 27: FDA Approved Targeted Therapeutic Agents for Brain Tumors
Table 28: Monoclonal Antibodies
Table 29: Small Molecule Monoclonal Antibodies
Table 30: Current Brain Tumor Clinical Trials Involving Bevacizumab
Table 31: Current Brain Tumor Clinical Trials Involving Everolimus
Table 32: Current Brain Tumor Clinical Trials: Immunotherapy
Table 33: Global Neurology Market for Brain Tumor Therapeutics, by Region, Through 2024
Table 34: Promising Forthcoming Neuroscience Therapies in Late Stage
Table 35: Agents Currently in Phase III of Alzheimer’s Disease Drug Development, 2018
Table 36: Ongoing Clinical Trials and Product Pipeline Involving Major Players in Brain Tumor Therapeutics
Table 37: Acronyms Used in This Report
List of Figures
Summary Figure: Global Market Share for Neurology, by Disease Indication, 2018
Figure 1: Pharmaceutical Regulatory Pathways in the U.S and Europe
Figure 2: Global Market for Neurology, by Disease Indication, 2018-2024
Figure 3: Global Neurology Market Share for Anti-Parkinson's Drugs, by Drug Class, 2018
Figure 4: Global Neurology Market for Dopaminergic Drugs, 2018-2024
Figure 5: Global Neurology Market for Dopamine Agonist Drugs, 2018-2024
Figure 6: Global Neurology Market for Enzyme Inhibitors Drugs, 2018-2024
Figure 7: Global Neurology Market for Other Anti-Parkinson’s Drugs, 2018-2024
Figure 8: Global Neurology Market Share for Anti-Parkinson's Drugs, by Region, 2018
Figure 9: North American Neurology Market for Anti-Parkinson's Drugs, 2018-2024
Figure 10: European Neurology Market for Anti-Parkinson's Drugs, 2018-2024
Figure 11: Asia-Pacific Neurology Market for Anti-Parkinson's Drugs, 2018-2024
Figure 12: South American Neurology Market for Anti-Parkinson's Drugs, 2018-2024
Figure 13: Middle Eastern and African Neurology Market for Anti-Parkinson's Drugs, 2018-2024
Figure 14: Global Market Share for Key Competitors of Anti-Parkinson’s Drugs, 2018
Figure 15: Global Neurology Market for Alzheimer AChEIs Drugs, 2018-2024
Figure 16: Global Neurology Market for Alzheimer NMDA Drugs, 2018-2024
Figure 17: Global Neurology Market Share for Alzheimer Drugs, by Region, 2018
Figure 18: North American Neurology Market for Alzheimer Drugs, 2018-2024
Figure 19: European Neurology Market for Alzheimer Drugs, 2018-2024
Figure 20: Rest of the World Neurology Market for Alzheimer Drugs, 2018-2024
Figure 21: Global Neurology Market Share for Antipsychotic Drugs, by Mechanism of Action, 2018
Figure 22: Global Neurology Market for Antipsychotic Drugs in D2 Antagonist, 2018-2024
Figure 23: Global Neurology Market for Antipsychotic Drugs in D2/5HT2A Antagonist, 2018-2024
Figure 24: Global Neurology Market for Antipsychotic Drugs in D2 Partial Agonist, 2018-2024
Figure 25: Global Neurology Market Share for Antipsychotic Drugs, by Region, 2018
Figure 26: North American Neurology Market for Antipsychotic Drugs, 2018-2024
Figure 27: European Neurology Market for Antipsychotic Drugs, 2018-2024
Figure 28: Asia-Pacific Neurology Market for Antipsychotic Drugs, 2018-2024
Figure 29: South American Neurology Market for Antipsychotic Drugs, 2018-2024
Figure 30: Middle Eastern and African Neurology Market for Antipsychotic Drugs, 2018-2024
Figure 31: Global Neurology Market Share for Antipsychotic Drugs, by Manufacturer, 2018
Figure 32: Global Neurology Market Share for Anti-Epileptic Drugs, by Segment, 2018
Figure 33: Global Neurology Market for First Generation Anti-Epileptic Drugs, 2018-2024
Figure 34: Global Neurology Market for Second Generation Anti-Epileptic Drugs, 2018-2024
Figure 35: Global Neurology Market for Third Generation Anti-Epileptic Drugs, 2018-2024
Figure 36: Global Neurology Market Share for Anti-Epileptic Drugs, by Region, 2018
Figure 37: North American Neurology Market for Anti-Epileptic Drugs, 2018-2024
Figure 38: European Neurology Market for Anti-Epileptic Drugs, 2018-2024
Figure 39: Asia-Pacific Neurology Market for Anti-Epileptic Drugs, 2018-2024
Figure 40: South American Neurology Market for Anti-Epileptic Drugs, 2018-2024
Figure 41: Middle Eastern and African Neurology Market for Anti-Epileptic Drugs, 2018-2024
Figure 42: Global Neurology Market Share for Anti-Epileptic Drugs, by Manufacturer, 2018
Figure 43: Global Neurology Market Share for ASD Therapeutics, by Label Information, 2018
Figure 44: Global Neurology Market for Labeled ASD Drugs, 2018-2024
Figure 45: Global Neurology Market for Off-label Pharmaceuticals ASD, 2018-2024
Figure 46: Global Neurology Market Share for ASD Therapeutics, by Region, 2018
Figure 47: North American Neurology Market for ASD Therapeutics, 2018-2024
Figure 48: European Neurology Market for ASD Therapeutics, 2018-2024
Figure 49: Rest of the World Neurology Market for ASD Therapeutics, 2018-2024
Figure 50: Global Neurology Market Share for Brain Tumor Therapeutics, by Therapy Type, 2018
Figure 51: Global Neurology Market for Brain Tumor Chemotherapy, 2018-2024
Figure 52: Global Neurology Market for Brain Tumor Targeted Therapy, 2018-2024
Figure 53: Targeted Therapy Types
Figure 54: Global Neurology Market Share for Brain Tumor Therapeutics, by Region, 2018
Figure 55: North American Neurology Market for Brain Tumor Therapeutics, 2018-2024
Figure 56: North American Incidence of Brain Tumors, 2018-2040
Figure 57: European Neurology Market for Brain Tumor Therapeutics, 2018-2024
Figure 58: European Incidence of Brain Tumors, 2018-2040
Figure 59: Asia-Pacific Neurology Market for Brain Tumor Therapeutics, 2018-2024
Figure 60: Asia-Pacific Incidence of Brain Tumors, 2018-2040
Figure 61: ROW Neurology Market for Brain Tumor Therapeutics, 2018-2024
Figure 62: Shares of Major Players in Brain Tumor Therapeutics Market, 2018
